Paper20197387
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Novotny-Diermayr V and 16 others. Mol Cancer Ther, 2010. Cited by 113 papers, by iCite.
Cite this record
ConductScience Library. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Papers, record 20197387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20197387
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Histone Deacetylase Inhibitors | Major topic |
| Hydroxamic Acids | Major topic |
| Administration, Oral | |
| Animals | |
| Antineoplastic Agents | |
| Biological Availability | |
| Female | |
| HCT116 Cells | |
| Humans | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Neoplasms | |
| Treatment Outcome | |
| Tumor Cells, Cultured | |
| Vorinostat | |
| Xenograft Model Antitumor Assays |
Source PubMed
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 113 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42415186 | Mapping the Safety Profile of Histone Deacetylase Inhibitors in Children with Cancer. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/42415186 | PubMed |
| 41473577 | Thermal shift engagement assay for Class IIA histone deacetylase inhibitor screening. | Results Chem | 2025 | https://conductscience.org/library/papers/41473577 | PubMed |
| 40805121 | Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40805121 | PubMed |
| 40775761 | Assessing the selective impact of histone modifying drugs on adenoid cystic carcinoma cells and their stem cell counterparts. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40775761 | PubMed |
| 40283883 | Advanced High-Content Phenotypic Screening to Identify Drugs That Ameliorate the Inhibition of Skeletal Muscle Cell Differentiation Induced by Cancer Cachexia Serum. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40283883 | PubMed |
| 40151421 | Effects of SB939 are mediated by STAT3 to inhibit breast cancer cell metastasis-related genes. | Oncol Lett | 2025 | https://conductscience.org/library/papers/40151421 | PubMed |
| 40027347 | Synthesis of fluorinated tubastatin A derivatives with bi-, tri-, and tetracyclic cap groups: molecular docking with HDAC6 and evaluation of in vitro antitumor activity. | RSC Med Chem | 2025 | https://conductscience.org/library/papers/40027347 | PubMed |
| 39801754 | Targeting the epigenome with advanced delivery strategies for epigenetic modulators. | Bioeng Transl Med | 2025 | https://conductscience.org/library/papers/39801754 | PubMed |
| 39136440 | Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir. | mBio | 2024 | https://conductscience.org/library/papers/39136440 | PubMed |
| 38465731 | Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer. | J Enzyme Inhib Med Chem | 2024 | https://conductscience.org/library/papers/38465731 | PubMed |
| 37711592 | Medicinal chemistry advances in targeting class I histone deacetylases. | Explor Target Antitumor Ther | 2023 | https://conductscience.org/library/papers/37711592 | PubMed |
| 36148005 | Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/36148005 | PubMed |
| 35622308 | The novel histone deacetylase inhibitor pracinostat suppresses the malignant phenotype in human glioma. | Mol Biol Rep | 2022 | https://conductscience.org/library/papers/35622308 | PubMed |
| 34677780 | Drug target inference by mining transcriptional data using a novel graph convolutional network framework. | Protein Cell | 2022 | https://conductscience.org/library/papers/34677780 | PubMed |
| 33999145 | Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. | Blood Adv | 2021 | https://conductscience.org/library/papers/33999145 | PubMed |
| 33628709 | Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy. | In Silico Pharmacol | 2021 | https://conductscience.org/library/papers/33628709 | PubMed |
| 33266366 | Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33266366 | PubMed |
| 32365701 | Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment? | Pharmaceutics | 2020 | https://conductscience.org/library/papers/32365701 | PubMed |
| 32212730 | Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. | J Med Chem | 2020 | https://conductscience.org/library/papers/32212730 | PubMed |
| 32019149 | Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer. | Biomedicines | 2020 | https://conductscience.org/library/papers/32019149 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20197387
GET https://conductscience.org/api/papers/v1/20197387/cited_by?page=2